Advertisement

Picture [iito] Made Without Love 650x80px
Document › Details

Owlstone Medical Ltd.. (3/30/20). "Press Release: Owlstone Medical Appoints Neil Tween as Chief Financial Officer". Cambridge.

Organisations Organisation Owlstone Medical Ltd.
  Group Owlstone (Group)
  Organisation 2 GW Pharmaceuticals plc
Products Product Breath Biopsy® platform
  Product 2 mass spectrometry (MS)
Persons Person Tween, Neil (Owlstone 202003– CFO at Owlstone Medical before GW Pharmaceuticals + Jagex + Deloitte)
  Person 2 Boyle, Billy (Owlstone 201606 CEO + Co-Founder of Owlstone Medical Ltd)
     


Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine today announces the appointment of Neil Tween as its new Chief Financial Officer.

Owlstone Medical is in the unique position of establishing a new diagnostic modality in breath that has substantial advantages over blood as a core sample type for clinicians and for academic and pharmaceutical researchers for the early detection of disease and to enable precision medicine approaches to patient care.

Over the coming period the focus of the business is on execution, building on commercial success with major clients for additional deals and repeat business, launching innovative breath tests to the market in areas of high clinical need with large market opportunities, and supporting growth ambitions by deepening internal systems and infrastructure and securing sufficient financing to enable the potential of Breath Biopsy to be realized.

Neil joins Owlstone Medical from GW Pharmaceuticals, a publicly listed (NASDAQ: GWPH) pharmaceutical company, where he served as Vice President and Group Financial Controller. During his tenure, Neil helped oversee the maturation of the company from a medium-sized UK-listed partner-funded R&D company to a 900-person global commercial organisation. Over this period, he demonstrated broad knowledge of international financial reporting standards and SEC compliance, was significantly involved in over $1 billion of public markets fundraising, and built the finance teams and systems needed to support the rapid growth of the business.

Prior to this, Neil acted as Financial Controller at Jagex Ltd., and spent six years with Deloitte, advising a range of listed and private biotech and pharmaceutical clients. Neil is a chartered accountant and is a Fellow of the Institute of the Accountants in England and Wales (ICAEW).

Neil Tween, CFO at Owlstone Medical, commented: “I am delighted to be joining Owlstone Medical at this exciting time and look forward to contributing to the growth of the business as it pursues its important mission to save over 100,000 lives and $1.5 billion in healthcare costs.”

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Neil is an excellent addition to the world-class team we have built at Owlstone Medical to realize the potential of Breath Biopsy in a wide range of applications including oncology and liver disease.” He continued: “He brings the experience and financial discipline that will see us through this important next phase of growth, and I and the Board welcome him to the team.”


ENDS


Notes to Editors:

For a high-resolution image, please contact Zyme Communications.
Neil Tween, CFO Owlstone Medical

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.


For more information please contact:

Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0) 7771730919

Or

Frazer Hall, Citigate Dewe Rogerson
Frazer.Hall@citigatedewerogerson.com
+44 (0) 20 7282 2822
 

About Owlstone Medical www.owlstonemedical.com

Owlstone Medical’s vision is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®. Breath Biopsy operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources such as diet or medication, changes in which can be characteristic of specific disease or indicate environmental exposure.

The Breath Biopsy platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, UK, and the development of the world’s largest Digital Breath Biobank matched to patient phenotype.

Owlstone Medical is deploying the platform to address some of the key challenges of 21st century healthcare. The focus is on the early detection of disease with an emphasis on cancer, with clinical trials underway to develop breath tests for the early detection of lung and colorectal cancer, and on precision medicine through partnerships with large pharmaceutical companies including AstraZeneca, Actelion Pharmaceuticals (a J&J company), and GlaxoSmithKline to enable therapeutics to be deployed more effectively. Owlstone Medical’s technology is currently in use at over 100 sites worldwide.

Follow Owlstone Medical on Twitter @OwlstoneMedical and LinkedIn @Owlstone Medical

   
Record changed: 2020-04-01

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

More documents for Owlstone (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top